Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 70/100

Failure Rate

14.3%

1 terminated/withdrawn out of 7 trials

Success Rate

50.0%

-36.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 1
6(85.7%)
Phase 2
1(14.3%)
7Total
Phase 1(6)
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials
NCT07576699Phase 1Not Yet Recruiting

CK0802 for Treatment of Steroid Refractory Graft vs. Host Disease (GVHD)

Role: lead

NCT07499102Phase 2Not Yet Recruiting

CK0801 for Treatment of Aplastic Anemia

Role: lead

NCT03773393Phase 1Active Not Recruiting

A Clinical Trial of CK0801 (a New Drug) in Patients With Bone Marrow Failure Syndrome (BMF)

Role: lead

NCT05423691Phase 1Recruiting

Leading in MPNs Beyond Ruxolitinib in Combo With T-Regs

Role: lead

NCT05695521Phase 1Active Not Recruiting

Regulatory T Cells for Amyotrophic Lateral Sclerosis

Role: lead

NCT03773328Phase 1Withdrawn

A Clinical Trial of CK0801 (a New Drug) In Patients With Treatment-Resistant Guillain-Barré Syndrome (GBS)

Role: lead

NCT04468971Phase 1Completed

REgulatory T Cell infuSion fOr Lung Injury Due to COVID-19 PnEumonia

Role: lead

All 7 trials loaded